We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+13.51%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.22B
AUM Growth
+$345M
Cap. Flow
-$140M
Cap. Flow %
-6.29%
Top 10 Hldgs %
38.04%
Holding
103
New
16
Increased
23
Reduced
25
Closed
12

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$82.9M
2
MCK icon
McKesson
MCK
+$64.6M
3
GKOS icon
Glaukos
GKOS
+$62M
4
VTRS icon
Viatris
VTRS
+$60.6M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$34.6M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$68.6M
2
GILD icon
Gilead Sciences
GILD
+$66.4M
3
NXTM
NxStage Medical Inc.
NXTM
+$60.1M
4
NVRO
NEVRO CORP.
NVRO
+$28M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.5M

Sector Composition

Rank Sector Weight
1 Healthcare 76.21%
2 Financials 0.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNC icon
51
Centene
CNC
$32.6B
$9.87M 0.44%
204,000
-34,000
-14% -$1.46M
SGMO
52
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$9.79M 0.44%
653,000
-441,305
-40% -$4.88M
NVTA
53
DELISTED
Invitae Corporation
NVTA
$8.43M 0.38%
+900,000
New +$8.55M
ALIM
54
DELISTED
Alimera Sciences
ALIM
$8.17M 0.37%
403,529
+85,559
+27% +$1.83M
IMMU
55
DELISTED
Immunomedics Inc
IMMU
$8.14M 0.37%
+582,000
New +$5.8M
MRNS
56
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$7.95M 0.36%
+338,750
New +$3.8M
CMTA
57
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$7.81M 0.35%
+462,387
New +$7.56M
NCNA
58
NuCana
NCNA
$5.37M
$7.81M 0.35%
+85
New +$7.34M
SIOX
59
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$7.24M 0.33%
131,500
+101,602
+340% +$17.1M
AXGN icon
60
Axogen
AXGN
$2.09B
$6.67M 0.3%
344,428
-330,000
-49% -$5.54M
MCK icon
61
CALL
McKesson
MCK
$97.4B
$6.64M 0.3%
+43,200
New +$6.74M
MYOV
62
DELISTED
Myovant Sciences Ltd.
MYOV
$6.2M 0.28%
400,685
– –
DCPH
63
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$6.17M 0.28%
+325,000
New +$5.95M
BHVN
64
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$6.17M 0.28%
165,000
-51,761
-24% -$1.57M
RETA
65
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.91M 0.27%
+190,000
New +$5.71M
AGRX
66
DELISTED
Agile Therapeutics
AGRX
$5.45M 0.25%
611
+133
+28% +$1.02M
STDY
67
DELISTED
SteadyMed Ltd
STDY
$4.75M 0.21%
1,418,787
-23,126
-2% -$123K
FOMX
68
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$4.54M 0.2%
817,435
– –
SRRA
69
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.34M 0.2%
70,000
-17,393
-20% -$1.02M
SAGE
70
DELISTED
Sage Therapeutics
SAGE
$4.24M 0.19%
+68,000
New +$5.34M
ARLZ
71
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$3.77M 0.17%
1,644,583
– –
HIND
72
Vyome Holdings
HIND
$15.2M
– –
0
– –
OPCH icon
73
Option Care Health
OPCH
$3.43B
$3.04M 0.14%
276,792
-55,200
-17% -$624K
AKTX
74
Akari Therapeutics
AKTX
$19.1M
$2.66M 0.12%
542
-481
-47% -$1.8M
TARA icon
75
Protara Therapeutics
TARA
$229M
$2.45M 0.11%
30,622
– –
1 2
3
4

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2017 Portfolio in Review

As of Q3 2017, Deerfield Management held 103 positions worth $2.22B, up 18% from $1.87B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Deerfield Management withdrew a net $140M in Q3 2017, closing 12 positions and reducing 25 holdings. Its most notable exit was Gilead Sciences, an estimated $66.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 72% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Insulet worth $27.4M.

  • Deerfield Management's largest Q3 2017 buy was Insulet: 497,000 shares worth $27.4M.
  • Deerfield Management added most to DexCom in Q3 2017, an estimated $82.9M increase.
  • Deerfield Management's biggest Q3 2017 reduction was AveXis, Inc. Common Stock, cutting an estimated $68.6M.
  • Deerfield Management fully exited Gilead Sciences in Q3 2017, selling an estimated $66.4M.
  • Deerfield Management's ten largest holdings make up 38% of its $2.22B portfolio in Q3 2017.
  • Deerfield Management opened 16 new positions and closed 12 in Q3 2017.
  • Deerfield Management's portfolio value rose 18% quarter-over-quarter to $2.22B.

Based on Deerfield Management's 13F filing for Q3 2017, filed 13 Nov 2017.